The second AD CSF biomarker is p-tau, which reflects tau phosphorylation and increases by around 200% from control levels in AD, most likely before the onset of the prodromal stage, and remains steady and high thereafter [48,49]. The gene discussed is MAPT; the disease is Alzheimer disease.